Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Pancreatic cancer genomics

(2014) David K Chang et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer

(2014) Alakesh Bera et al.   PLoS One

The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytoametry

(2013) Maria Watson et al.   CYTOMETRY PART A

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

(2013) William Greenhalf et al.   JNCI-Journal of the National Cancer Institute

Evolution and dynamics of pancreatic cancer progression

(2013) S Yachida et al.   ONCOGENE

Cell motility and drug gradients in the emergence of resistance to chemotherapy

(2013) A. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heterogeneity and Targeting of Pancreatic Cancer Stem Cells

(2012) V. R. Penchev et al.   CLINICAL CANCER RESEARCH

Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity

(2012) Y. Cui et al.   CLINICAL CANCER RESEARCH

Meta-Analysis of Gene Expression Signatures Defining the Epithelial to Mesenchymal Transition during Cancer Progression

(2012) Christian J. Gröger et al.   PLoS One

Notch Signaling Activated by Replication Stress-Induced Expression of Midkine Drives Epithelial-Mesenchymal Transition and Chemoresistance in Pancreatic Cancer

(2011) C. Gungor et al.   CANCER RESEARCH

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704

(2011) J J Farrell et al.   PHARMACOGENOMICS JOURNAL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Advanced pancreatic carcinoma: current treatment and future challenges

(2010) Anastasios Stathis et al.   Nature Reviews Clinical Oncology

Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells

(2009) Y. Li et al.   CANCER RESEARCH

Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

(2009) Z. Wang et al.   CANCER RESEARCH

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

(2009) T. Arumugam et al.   CANCER RESEARCH

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma

(2008) S.-S. Liau et al.   CLINICAL CANCER RESEARCH

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE